GOH Wan Yee

Senior Vice President, Healthcare
Singapore Economic Development Board (EDB)
​​

Wan Yee is the Senior Vice President and Head for Healthcare in the Singapore Economic Development Board (EDB).  She oversees the industry development strategies and engagement of international companies to facilitate investments in Singapore, and works closely with relevant stakeholders to enhance our public research and innovation ecosystem. 

Wan Yee is a board member of the Consortium for Clinical Research and Innovation, Singapore (CRIS), and serves on the board oversight committees of Precision Health Research Singapore (PRECISE) and Advanced Cell Therapy and Research Institute, Singapore (ACTRIS). She is also on the governing board of Experimental Drug Development Centre (EDDC) and the steering board of Pharmaceutical Innovation Programme Singapore (PIPS). She co-chairs Singapore’s Biopharmaceutical Manufacturer’s Advisory Council (BMAC) and is on the industry advisory council of Singapore Institute of Technology’s (SIT) Pharmaceutical Engineering programme.

Prior to this, Wan Yee led EDB's Human Capital team and was responsible for working closely with companies, industry associations, unions and Singapore's manpower agencies to attract and develop talent for our wide range of industries. She also spent some time in EDB’s Human Resources and has a depth of knowledge across various HR functions.  

Wan Yee started her EDB career in the then nascent Biomedical Sciences cluster and was part of the team that spearheaded the growth of this industry.  This included a stint in Bio*One Capital, a venture capital arm of EDB that invests in biotechnology and medical technology start-ups.

She is trained as a Chemical Engineer and worked as a Process Engineer in ExxonMobil before joining EDB. In her personal capacity, Wan Yee serves on the SingHealth Community Hospital Fund Committee and the Singapore Canoe Federation Board.

 

 

Speech title & Synopsis

Singapore: Bridging East-West Biotech Opportunities  

Presented by the Singapore Economic Development Board (EDB), Singapore's lead government agency for industry development and investment promotion, this session explores Singapore's pivotal role in bridging Eastern and Western biotech opportunities. 

Built on more than two decades of strategic investments, Singapore's Biomedical Sciences industry has become a cornerstone of the economy, contributing 2.6% to GDP and manufacturing nearly S$38 billion worth of products for global markets in 2023.

Drawing from concrete case studies, the presentation will discuss how Singapore facilitates cross-border investment flows and commercial partnerships, enabling Eastern biotech innovations to reach Western pharmaceutical companies while helping Western firms expand their footprint in Asian markets. 

Participants will gain insights into Singapore's regulatory excellence, as well as world-class pharmaceutical and medical technology manufacturing capabilities, serving global markets through a robust export network. It will also showcase Singapore's innovation ecosystem, from advanced process development and automation to breakthrough drug discovery initiatives, illustrating how the city-state is catalysing the next wave of biomedical advancement.

Join us to understand how Singapore's unique position and capabilities can benefit your organisation's global biotech aspirations.

​

​

​

 

​